A Phase III Study of Efficacy and Safety of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03580356 |
|
Recruitment Status :
Active, not recruiting
First Posted : July 9, 2018
Last Update Posted : May 23, 2022
|
Sponsor:
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of this study is to establish efficacy and safety of ligelizumab in adolescent and adult subjects with CSU who remain symptomatic despite standard of care treatment by demonstrating better efficacy over omalizumab and over placebo.
The study population will consist of approximately 1050 male and female subjects aged ≥ 12 years who have been diagnosed with CSU and who remain symptomatic despite the use of H1-antihistamines. Of these, approximately 1000 adults and 50 adolescents are planned for inclusion in the study.
This is a multi-center, randomized, double-blind, active- and placebo-controlled, parallel-group study. There is a screening period of up to 28 days, a 52 week double-blind treatment period, and a 12 week post-treatment follow-up period.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Chronic Spontaneous Urticaria | Biological: Ligelizumab Biological: Omalizumab Other: Placebo | Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 1078 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | This is a Phase III multi-center, randomized, double-blind, active- and placebo-controlled, parallel-group study. There is a screening period of up to 28 days, a 52 week double-blind treatment period, and a 12 week post-treatment follow-up period. |
| Masking: | Triple (Participant, Care Provider, Investigator) |
| Masking Description: | Patients, investigator staff and personnel performing the study assessments will remain blinded to the identity of the treatment from the time of randomization until final database lock. The study drug must be prepared by an independent unblinded pharmacist (or authorized delegate) and administered by an independent unblinded study drug administrator. Neither the unblinded pharmacist nor the unblinded study drug administrator will be involved in any assessments. |
| Primary Purpose: | Treatment |
| Official Title: | A Multi-center, Randomized, Double-blind, Active and Placebo-controlled Study to Investigate the Efficacy and Safety of Ligelizumab (QGE031) in the Treatment of Chronic Spontaneous Urticaria (CSU) in Adolescents and Adults Inadequately Controlled With H1-antihistamines |
| Actual Study Start Date : | October 20, 2018 |
| Actual Primary Completion Date : | June 22, 2021 |
| Estimated Study Completion Date : | June 21, 2022 |
Resource links provided by the National Library of Medicine
Drug Information available for:
Omalizumab
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Ligelizumab Dose A
Ligelizumab Dose A q4w
|
Biological: Ligelizumab
Liquid in vial |
|
Experimental: Ligelizumab Dose B
Ligelizumab Dose B q4w
|
Biological: Ligelizumab
Liquid in vial |
|
Active Comparator: Omalizumab 300 mg
Omalizumab 300 mg q4w
|
Biological: Omalizumab
Lyophilized powder for solution in vial |
|
Placebo Comparator: Placebo
Placebo q4w from randomization to week 20. Ligelizumab Dose B from week 24 to week 48.
|
Other: Placebo
Liquid in vial |
Primary Outcome Measures :
- Absolute change from baseline in UAS7 at Week 12 [ Time Frame: Week 12 ]
The Urticaria Activity Score (UAS) is the sum of the Hive Severity Score (HSS) and the Itch Severity Score (ISS).
The HSS has a scale of 0 (none) to 3 (intense/severe). A weekly score (HSS7) is derived by adding up the average daily scores of the preceding 7 days.
The ISS also has a scale of 0 (none) to 3 (severe/difficult to tolerate). A weekly score (ISS7) is derived by adding up the average daily scores of the preceding 7 days.
The UAS7 is the sum of the HSS7 score and the ISS7 score, and has a possible range in score of 0-42.
Complete hives response is defined as HSS7 (average daily HSS over the preceding 7 days) = 0.
Complete itch response is defined as ISS7 (average daily ISS over the preceding 7 days) = 0.
Complete UAS7 response is defined as UAS7=0.
Secondary Outcome Measures :
- Complete absence of hives and itch at Week 12 [ Time Frame: Week 12 ]Assessed as percentage of subjects achieving UAS7 = 0
- Improvement of severity of itch [ Time Frame: Week 12 ]Assessed as absolute change from baseline in ISS7 score at Week 12
- No impact on subject's quality of life at Week 12 [ Time Frame: Week 12 ]Assessed as percentage of subjects achieving DLQI = 0-1
- Cumulative number of weeks that subjects achieve AAS7 = 0 responses between baseline and Week 12 [ Time Frame: Weekly to Week 12 ]To assess the cumulative period of time that treated subjects are angioedema occurrence-free
- Occurrence of treatment emergent adverse events and serious adverse events during the study [ Time Frame: 52 weeks ]Treatment emergent adverse events and serious adverse events are those which occur at any time only after treatment has started
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 12 Years and older (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Key Inclusion Criteria:
- Signed informed consent must be obtained prior to participation in the study. The subject's', parent'ssubject's, parent's or legal guardian's signed written informed consent and child's assent, if appropriate, must be obtained before any assessment is performed. Of note, if the subject reaches age of consent (age as per local law) during the study, they will also need to sign the corresponding study Informed Consent Form (ICF) at the next study visit.
- Male and female subjects ≥ 12 years of age at the time of screening.
- CSU diagnosis for ≥ 6 months.
- Diagnosis of CSU refractory to H1-AH at approved doses at the time of randomization, as defined by all of the following:
- The presence of itch and hives for ≥ 6 consecutive weeks at any time prior to Visit 1 (Day - 28 to Day -14) despite current use of non-sedating H1-AH
- UAS7 score (range 0-42) ≥ 16 and HSS7 (range 0-21) ≥ 8 during the 7 days prior to randomization (Visit 110, Day 1)
- Subjects must be on H1-AH at only approved doses for treatment of CSU starting at Visit 1 (Day -28 to Day -14)
- Willing and able to complete a daily symptom eDiary for the duration of the study and adhere to the study visit schedules.
Key Exclusion Criteria:
- History of hypersensitivity to any of the study drugs or their excipients or to drugs of similar chemical classes (i.e. to murine, chimeric or human antibodies).
- Subjects having a clearly defined cause of their chronic urticaria, other than CSU. This includes, but is not limited to, the following: symptomatic dermographism (urticaria factitia), cold-, heat-, solar-, pressure-, delayed pressure-, aquagenic-, cholinergic- or contact-urticaria.
- Diseases, other than chronic urticaria, with urticarial or angioedema symptoms such as urticarial vasculitis, erythema multiforme, cutaneous mastocytosis (urticaria pigmentosa) and hereditary or acquired angioedema (eg, due to C1 inhibitor deficiency).
- Subjects with evidence of helminthic parasitic infection as evidenced by stools being positive for a pathogenic organism according to local guidelines. All subjects will be screened at Visit 1. If stool testing is positive for pathogenic organism, the subject will not be randomized and will not be allowed to rescreen.
- Any other skin disease associated with chronic itching that might influence in the investigators opinion the study evaluations and results (e.g. atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus, etc.).
- Prior exposure to ligelizumab or omalizumab.
- Any H2 antihistamine, LTRA (montelukast or zafirlukast) or H1 antihistamines use at greater than approved doses after Visit 1.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03580356
Locations
Hide 183 study locations
| United States, Alabama | |
| Novartis Investigative Site | |
| Birmingham, Alabama, United States, 35209 | |
| United States, Arizona | |
| Novartis Investigative Site | |
| Scottsdale, Arizona, United States, 85251 | |
| United States, Arkansas | |
| Novartis Investigative Site | |
| Little Rock, Arkansas, United States, 72209 | |
| United States, California | |
| Novartis Investigative Site | |
| Fresno, California, United States, 93720 | |
| Novartis Investigative Site | |
| Los Angeles, California, United States, 90025 | |
| Novartis Investigative Site | |
| Redwood City, California, United States, 94063 | |
| Novartis Investigative Site | |
| San Jose, California, United States, 95117 | |
| United States, Florida | |
| Novartis Investigative Site | |
| Sarasota, Florida, United States, 34233 | |
| Novartis Investigative Site | |
| Tampa, Florida, United States, 33609 | |
| United States, Idaho | |
| Novartis Investigative Site | |
| Eagle, Idaho, United States, 83616 | |
| United States, Illinois | |
| Novartis Investigative Site | |
| Normal, Illinois, United States, 61761 | |
| United States, Maryland | |
| Novartis Investigative Site | |
| Baltimore, Maryland, United States, 21204 | |
| Novartis Investigative Site | |
| Wheaton, Maryland, United States, 20902 | |
| Novartis Investigative Site | |
| White Marsh, Maryland, United States, 21162 | |
| United States, Minnesota | |
| Novartis Investigative Site | |
| Rochester, Minnesota, United States, 55905 | |
| United States, Missouri | |
| Novartis Investigative Site | |
| Saint Louis, Missouri, United States, 63141 | |
| United States, Montana | |
| Novartis Investigative Site | |
| Missoula, Montana, United States, 59808 | |
| United States, Nebraska | |
| Novartis Investigative Site | |
| Papillion, Nebraska, United States, 68046 | |
| United States, New York | |
| Novartis Investigative Site | |
| New York, New York, United States, 10029 | |
| United States, Ohio | |
| Novartis Investigative Site | |
| Toledo, Ohio, United States, 43617 | |
| United States, Oklahoma | |
| Novartis Investigative Site | |
| Oklahoma City, Oklahoma, United States, 73120 | |
| United States, Oregon | |
| Novartis Investigative Site | |
| Clackamas, Oregon, United States, 97015 | |
| United States, Pennsylvania | |
| Novartis Investigative Site | |
| Blue Bell, Pennsylvania, United States, 19422 | |
| Novartis Investigative Site | |
| Pittsburgh, Pennsylvania, United States, 15241 | |
| United States, South Carolina | |
| Novartis Investigative Site | |
| North Charleston, South Carolina, United States, 29420 | |
| United States, Texas | |
| Novartis Investigative Site | |
| Bellaire, Texas, United States, 77401 | |
| Novartis Investigative Site | |
| El Paso, Texas, United States, 79903 | |
| Novartis Investigative Site | |
| Fort Worth, Texas, United States, 76132 | |
| Novartis Investigative Site | |
| San Antonio, Texas, United States, 78229 | |
| Novartis Investigative Site | |
| San Antonio, Texas, United States, 78230 | |
| Novartis Investigative Site | |
| Waco, Texas, United States, 76712 | |
| United States, Utah | |
| Novartis Investigative Site | |
| Murray, Utah, United States, 84107 | |
| United States, Washington | |
| Novartis Investigative Site | |
| Bellingham, Washington, United States, 98225 | |
| Argentina | |
| Novartis Investigative Site | |
| Caba, Buenos Aires, Argentina, C1181ACH | |
| Novartis Investigative Site | |
| Caba, Buenos Aires, Argentina, C1414AIF | |
| Novartis Investigative Site | |
| Ciudad de Mendoza, Mendoza, Argentina, M5500AWD | |
| Novartis Investigative Site | |
| Santa Fe, Rosario, Argentina, S2000DBS | |
| Novartis Investigative Site | |
| Rosario, Santa Fe, Argentina, S2000BRH | |
| Novartis Investigative Site | |
| Rosario, Santa Fe, Argentina, S2000JKR | |
| Novartis Investigative Site | |
| Buenos Aires, Argentina, C1425DKG | |
| Novartis Investigative Site | |
| Caba, Argentina, 1035 | |
| Novartis Investigative Site | |
| Salta, Argentina, 4400 | |
| Australia, South Australia | |
| Novartis Investigative Site | |
| Adelaide, South Australia, Australia, 5000 | |
| Australia, Victoria | |
| Novartis Investigative Site | |
| East Melbourne, Victoria, Australia, 3002 | |
| Novartis Investigative Site | |
| Parkville, Victoria, Australia, 3002 | |
| Belgium | |
| Novartis Investigative Site | |
| Jette, Brussel, Belgium, 1090 | |
| Novartis Investigative Site | |
| Bruxelles, Belgium, 1070 | |
| Novartis Investigative Site | |
| Bruxelles, Belgium, 1200 | |
| Novartis Investigative Site | |
| Gent, Belgium, 9000 | |
| Novartis Investigative Site | |
| Leuven, Belgium, 3000 | |
| Novartis Investigative Site | |
| Loverval, Belgium, 6280 | |
| Brazil | |
| Novartis Investigative Site | |
| Salvador, BA, Brazil, 40110-060 | |
| Novartis Investigative Site | |
| Rio de Janeiro, RJ, Brazil, 21941-913 | |
| Novartis Investigative Site | |
| Alphaville Barueri, Sao Paulo, Brazil, 06454010 | |
| Novartis Investigative Site | |
| Sao Jose do Rio Preto, SP, Brazil, 15090 000 | |
| Novartis Investigative Site | |
| Sao Paulo, SP, Brazil, 05437 010 | |
| Chile | |
| Novartis Investigative Site | |
| Vitacura, Santiago, Chile, 7640881 | |
| Novartis Investigative Site | |
| Osorno, Chile | |
| Novartis Investigative Site | |
| Santiago, Chile, 8420383 | |
| Estonia | |
| Novartis Investigative Site | |
| Tallinn, Estonia, 10138 | |
| Novartis Investigative Site | |
| Tartu, Estonia, 51014 | |
| Finland | |
| Novartis Investigative Site | |
| Helsinki, Finland, 00180 | |
| France | |
| Novartis Investigative Site | |
| Clermont Ferrand, France, 63003 | |
| Novartis Investigative Site | |
| La Tronche, France, 38700 | |
| Novartis Investigative Site | |
| Nice Cedex, France, 06202 | |
| Novartis Investigative Site | |
| Paris, France, 75970 | |
| Novartis Investigative Site | |
| Rouen, France, 76031 | |
| Germany | |
| Novartis Investigative Site | |
| Bad Bentheim, Germany, 48455 | |
| Novartis Investigative Site | |
| Dresden, Germany, 01307 | |
| Novartis Investigative Site | |
| Duesseldorf, Germany, 40225 | |
| Novartis Investigative Site | |
| Frankfurt, Germany, 60590 | |
| Novartis Investigative Site | |
| Gera, Germany, 07548 | |
| Novartis Investigative Site | |
| Gottingen, Germany, 37075 | |
| Novartis Investigative Site | |
| Halle, Germany, 06097 | |
| Novartis Investigative Site | |
| Hamburg, Germany, 22303 | |
| Novartis Investigative Site | |
| Hamburg, Germany, 22391 | |
| Novartis Investigative Site | |
| Hannover, Germany, 30625 | |
| Novartis Investigative Site | |
| Heidelberg, Germany, 69120 | |
| Novartis Investigative Site | |
| Leipzig, Germany, 04103 | |
| Novartis Investigative Site | |
| Muenchen, Germany, 80377 | |
| Novartis Investigative Site | |
| Osnabrueck, Germany, 49074 | |
| Novartis Investigative Site | |
| Quedlinburg, Germany, 06484 | |
| Novartis Investigative Site | |
| Simmern, Germany, 55469 | |
| Novartis Investigative Site | |
| Stade, Germany, 21682 | |
| Novartis Investigative Site | |
| Stuttgart, Germany, 70178 | |
| Novartis Investigative Site | |
| Tübingen, Germany, 72076 | |
| India | |
| Novartis Investigative Site | |
| New Delhi, Delhi, India, 110 060 | |
| Novartis Investigative Site | |
| Bangalore, Karnataka, India, 560004 | |
| Novartis Investigative Site | |
| Mangalore, Karnataka, India, 575002 | |
| Novartis Investigative Site | |
| Nashik, Maharashtra, India, 422 101 | |
| Novartis Investigative Site | |
| Bikaner, Rajasthan, India, 334001 | |
| Israel | |
| Novartis Investigative Site | |
| Afula, Israel, 1834111 | |
| Novartis Investigative Site | |
| Haifa, Israel, 3339419 | |
| Novartis Investigative Site | |
| Jerusalem, Israel, 9112001 | |
| Novartis Investigative Site | |
| Kfar Saba, Israel, 4428164 | |
| Novartis Investigative Site | |
| Ramat Gan, Israel, 52621 | |
| Novartis Investigative Site | |
| Rehovot, Israel, 76100 | |
| Italy | |
| Novartis Investigative Site | |
| Cagliari, CA, Italy, 09042 | |
| Novartis Investigative Site | |
| Catania, CT, Italy, 95125 | |
| Novartis Investigative Site | |
| Firenze, FI, Italy, 50122 | |
| Novartis Investigative Site | |
| Firenze, FI, Italy, 50134 | |
| Novartis Investigative Site | |
| Rozzano, MI, Italy, 20089 | |
| Novartis Investigative Site | |
| Modena, MO, Italy, 41100 | |
| Novartis Investigative Site | |
| Siena, SI, Italy, 53100 | |
| Japan | |
| Novartis Investigative Site | |
| Nagoya, Aichi, Japan, 454-0012 | |
| Novartis Investigative Site | |
| Chikushino, Fukuoka, Japan, 818 0083 | |
| Novartis Investigative Site | |
| Hiroshima City, Hiroshima, Japan, 734-8551 | |
| Novartis Investigative Site | |
| Amagasaki city, Hyogo, Japan, 660 8550 | |
| Novartis Investigative Site | |
| Kobe-shi, Hyogo, Japan, 650-0017 | |
| Novartis Investigative Site | |
| Kawasaki, Kanagawa, Japan, 211-0063 | |
| Novartis Investigative Site | |
| Yokohama, Kanagawa, Japan, 220-6208 | |
| Novartis Investigative Site | |
| Yokohama, Kanagawa, Japan, 221-0825 | |
| Novartis Investigative Site | |
| Kamimashi-gun, Kumamoto, Japan, 861-3106 | |
| Novartis Investigative Site | |
| Sakai, Osaka, Japan, 593-8324 | |
| Novartis Investigative Site | |
| Izumo-city, Shimane, Japan, 693 8501 | |
| Novartis Investigative Site | |
| Itabashi-ku, Tokyo, Japan, 173-8610 | |
| Novartis Investigative Site | |
| Machida-city, Tokyo, Japan, 194-0013 | |
| Novartis Investigative Site | |
| Setagaya-ku, Tokyo, Japan, 158-0097 | |
| Novartis Investigative Site | |
| Shinagawa ku, Tokyo, Japan, 141 8625 | |
| Novartis Investigative Site | |
| Fukuoka, Japan, 819 0167 | |
| Lebanon | |
| Novartis Investigative Site | |
| Ashrafieh, Lebanon, 166830 | |
| Novartis Investigative Site | |
| Beirut, Lebanon, 166378 | |
| Novartis Investigative Site | |
| Saida, Lebanon, 652 | |
| Mexico | |
| Novartis Investigative Site | |
| Guadalajara, Jalisco, Mexico, 44130 | |
| Novartis Investigative Site | |
| Villahermosa, Tabasco, Mexico, 86035 | |
| Netherlands | |
| Novartis Investigative Site | |
| Breda, CK, Netherlands, 4818 CK | |
| Novartis Investigative Site | |
| Bergen op Zoom, Netherlands, 4624 VT | |
| Novartis Investigative Site | |
| Rotterdam, Netherlands, 3015 CE | |
| Novartis Investigative Site | |
| Utrecht, Netherlands, 3584CX | |
| Philippines | |
| Novartis Investigative Site | |
| Lipa City, Batangas, Philippines, 4217 | |
| Novartis Investigative Site | |
| Taguig City, Metro Manila, Philippines, 1634 | |
| Novartis Investigative Site | |
| Makati City, Philippines, 1220 | |
| Novartis Investigative Site | |
| Pasig City, Philippines, 1605 | |
| Novartis Investigative Site | |
| Quezon City, Philippines, 1102 | |
| Poland | |
| Novartis Investigative Site | |
| Warszawa, Mazowian, Poland, 02 495 | |
| Novartis Investigative Site | |
| Bydgoszcz, Poland, 85-094 | |
| Novartis Investigative Site | |
| Gdansk, Poland, 80-402 | |
| Novartis Investigative Site | |
| Krosno, Poland, 38-400 | |
| Novartis Investigative Site | |
| Lodz, Poland, 90-153 | |
| Novartis Investigative Site | |
| Lodz, Poland, 90-436 | |
| Novartis Investigative Site | |
| Ossy, Poland, 42 624 | |
| Novartis Investigative Site | |
| Sopot, Poland, 81 756 | |
| Novartis Investigative Site | |
| Warszawa, Poland, 02-507 | |
| Romania | |
| Novartis Investigative Site | |
| Bucharest, District 2, Romania, 020762 | |
| Novartis Investigative Site | |
| Brasov, Romania, 500283 | |
| Novartis Investigative Site | |
| Cluj Napoca, Romania, 400162 | |
| Novartis Investigative Site | |
| Craiova, Romania, 200642 | |
| Novartis Investigative Site | |
| Iasi, Romania, 700381 | |
| Russian Federation | |
| Novartis Investigative Site | |
| Chelyabinsk, Russian Federation, 454048 | |
| Novartis Investigative Site | |
| Kazan, Russian Federation, 420012 | |
| Novartis Investigative Site | |
| Moscow, Russian Federation, 115478 | |
| Novartis Investigative Site | |
| Saint Petersburg, Russian Federation, 191123 | |
| Novartis Investigative Site | |
| St Petersburg, Russian Federation, 194223 | |
| Novartis Investigative Site | |
| St.-Petersburg, Russian Federation, 195112 | |
| Novartis Investigative Site | |
| Stavropol, Russian Federation, 355000 | |
| Slovakia | |
| Novartis Investigative Site | |
| Levice, Slovak Republic, Slovakia, 934 01 | |
| Novartis Investigative Site | |
| Kezmarok, Slovakia, 060 01 | |
| Novartis Investigative Site | |
| Komarno, Slovakia, 945 01 | |
| Novartis Investigative Site | |
| Nove Zamky, Slovakia, 940 34 | |
| Novartis Investigative Site | |
| Povazska Bystrica, Slovakia, 017 26 | |
| Novartis Investigative Site | |
| Svidnik, Slovakia, 08901 | |
| Novartis Investigative Site | |
| Topolcany, Slovakia, 95501 | |
| Novartis Investigative Site | |
| Zilina, Slovakia, 010 01 | |
| Spain | |
| Novartis Investigative Site | |
| Cordoba, Andalucia, Spain, 14004 | |
| Novartis Investigative Site | |
| Barcelona, Catalunya, Spain, 08035 | |
| Novartis Investigative Site | |
| Valencia, Comunidad Valenciana, Spain, 46014 | |
| Novartis Investigative Site | |
| Valencia, Comunidad Valenciana, Spain, 46015 | |
| Novartis Investigative Site | |
| Valencia, Comunidad Valenciana, Spain, 46026 | |
| Novartis Investigative Site | |
| Alcorcon, Madrid, Spain, 28922 | |
| Novartis Investigative Site | |
| Pozuelo de Alarcon, Madrid, Spain, 28223 | |
| Novartis Investigative Site | |
| Pamplona, Navarra, Spain, 31008 | |
| Novartis Investigative Site | |
| La Laguna, Santa Cruz De Tenerife, Spain, 38320 | |
| Novartis Investigative Site | |
| Granada, Spain, 18012 | |
| Novartis Investigative Site | |
| Madrid, Spain, 28041 | |
| Taiwan | |
| Novartis Investigative Site | |
| Taichung, Taiwan, 40705 | |
| Novartis Investigative Site | |
| Taipei, Taiwan, 10002 | |
| Novartis Investigative Site | |
| Tao Yuan, Taiwan, 333 | |
| Tunisia | |
| Novartis Investigative Site | |
| Sfax, Tunusia, Tunisia, 3029 | |
| Novartis Investigative Site | |
| Sousse, Tunisia, 4000 | |
| Novartis Investigative Site | |
| Tunis, Tunisia, 1007 | |
| United Kingdom | |
| Novartis Investigative Site | |
| London, United Kingdom, SE1 7EH | |
| Vietnam | |
| Novartis Investigative Site | |
| Hanoi, Vietnam, 100000 | |
| Novartis Investigative Site | |
| Ho Chi Minh, Vietnam, 7000 | |
Sponsors and Collaborators
Novartis Pharmaceuticals
| Responsible Party: | Novartis Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT03580356 |
| Other Study ID Numbers: |
CQGE031C2303 2018-000840-24 ( EudraCT Number ) |
| First Posted: | July 9, 2018 Key Record Dates |
| Last Update Posted: | May 23, 2022 |
| Last Verified: | May 2022 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
|
Anti-IgE, CSU (Chronic Spontaneous Urticaria), hives severity score, itch severity score, urticaria activity score |
Additional relevant MeSH terms:
|
Urticaria Chronic Urticaria Skin Diseases, Vascular Skin Diseases Hypersensitivity, Immediate Hypersensitivity |
Immune System Diseases Omalizumab Anti-Allergic Agents Anti-Asthmatic Agents Respiratory System Agents |